nach oben

International Journal of Clinical Oncology

Erschienen in:

19.01.2025 | Original Article

Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma

verfasst von: Ryunosuke Nakagawa, Kouji Izumi, Ren Toriumi, Shuhei Aoyama, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Hiroaki Iwamoto, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Atsushi Mizokami

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2025

Einloggen, um Zugang zu erhalten

Abstract

Background

Enfortumab vedotin (EV) is a novel treatment for metastatic urothelial carcinoma (mUC) that progresses after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. This study aimed to compare the efficacy of EV with that of paclitaxel plus carboplatin therapy (TC), which was commonly used as late-line therapy.

Methods

This retrospective study included patients with mUC who progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. Patients were classified into two groups: those who were initiated on EV (EV group) and those who received TC as the next-line treatment (TC group). Therapeutic efficacy and adverse events (AEs) were investigated.

Results

A total of 55 patients were included in this study (20 in the TC group and 35 in the EV group). The EV group had significantly better progression-free survival (PFS) (p = 0.0013) and overall survival (OS) (p = 0.0279) than the TC group. The most frequent AEs were neutropenia (70.0%), febrile neutropenia (20.0%), and peripheral neuropathy (20.0%) in the TC group and pruritus (45.7%) and maculopapular rash (37.1%) in the EV group. Patients who progressed after EV administration were classified into two groups: those who received TC (the TC group) and those who were shifted to best supportive care (the BSC group). The TC group had significantly better OS (p = 0.0084).

Conclusions

EV was associated with significantly better PFS and OS than TC in patients with mUC who progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. TC is beneficial for certain patients, even in cases of progression after EV administration.

Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125–1135. https://doi.org/10.1056/NEJMoa2035807CrossRefPubMedPubMedCentral

Petrylak DP, de Wit R, Chi KN et al (2020) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 21:105–120. https://doi.org/10.1016/s1470-2045(19)30668-0CrossRefPubMed

McCaffrey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853–1857. https://doi.org/10.1200/jco.1997.15.5.1853CrossRefPubMed

Pronzato P, Vigani A, Pensa F et al (1997) Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 20:519–521. https://doi.org/10.1097/00000421-199710000-00018CrossRefPubMed

Witte RS, Elson P, Bono B et al (1997) Eastern cooperative oncology group Phase II Trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589–593. https://doi.org/10.1200/jco.1997.15.2.589CrossRefPubMed

Sonpavde G, Pond GR, Choueiri TK et al (2016) Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol 69:634–641. https://doi.org/10.1016/j.eururo.2015.07.042CrossRefPubMed

Vaishampayan UN, Faulkner JR, Small EJ et al (2005) Phase II Trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 104:1627–1632. https://doi.org/10.1002/cncr.21370CrossRefPubMed

Furubayashi N, Hori Y, Morokuma F et al (2021) Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma. Mol Clin Oncol 14:91. https://doi.org/10.3892/mco.2021.2253CrossRefPubMedPubMedCentral

Challita-Eid PM, Satpayev D, Yang P et al (2016) Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003–3013. https://doi.org/10.1158/0008-5472.Can-15-1313CrossRefPubMed

10.

Rosenberg J, Sridhar SS, Zhang J et al (2020) EV-101: A Phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 38:1041–1049. https://doi.org/10.1200/jco.19.02044CrossRefPubMedPubMedCentral

11.

Matsubara N, Yonese J, Kojima T et al (2023) Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med 12:2761–2771. https://doi.org/10.1002/cam4.5165CrossRefPubMed

12.

Taguchi S, Kawai T, Ambe Y et al (2023) Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study. Int J Urol 30:1180–1186. https://doi.org/10.1111/iju.15300CrossRefPubMed

13.

Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458. https://doi.org/10.1002/1097-0142(19891215)64:12%3c2448::aid-cncr2820641209%3e3.0.co;2-7CrossRefPubMed

14.

von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077. https://doi.org/10.1200/jco.2000.18.17.3068CrossRefPubMed

15.

Bellmunt J, Ribas A, Eres N et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966–1972. https://doi.org/10.1002/(sici)1097-0142(19971115)80:10%3c1966::aid-cncr14%3e3.0.co;2-wCrossRefPubMed

16.

Dogliotti L, Cartenì G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 Trial. Eur Urol 52:134–141. https://doi.org/10.1016/j.eururo.2006.12.029CrossRefPubMed

17.

Alfred Witjes J, Max Bruins H, Carrión A et al (2024) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85:17–31. https://doi.org/10.1016/j.eururo.2023.08.016CrossRefPubMed

18.

Nakagawa R, Izumi K, Toriumi R et al (2024) Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma. Jpn J Clin Oncol. https://doi.org/10.1093/jjco/hyae101CrossRefPubMedPubMedCentral

19.

Rawlings AV (2006) Ethnic skin types: are there differences in skin structure and function? Int J Cosmet Sci 28:79–93. https://doi.org/10.1111/j.1467-2494.2006.00302.xCrossRefPubMed

20.

Nguyen MN, Reyes M, Jones SC (2021) Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis. JAMA Dermatol 157:1237–1239. https://doi.org/10.1001/jamadermatol.2021.3450CrossRefPubMedPubMedCentral

Titel: Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma
verfasst von: Ryunosuke Nakagawa
Kouji Izumi
Ren Toriumi
Shuhei Aoyama
Hiroshi Kano
Tomoyuki Makino
Renato Naito
Suguru Kadomoto
Hiroaki Iwamoto
Hiroshi Yaegashi
Shohei Kawaguchi
Takahiro Nohara
Kazuyoshi Shigehara
Atsushi Mizokami
Publikationsdatum: 19.01.2025
Verlag: Springer Nature Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 3/2025
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-024-02678-x

Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies

Open Access
JSCO Board of Directors Series

The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma

Original Article

Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis

Open Access
Original Article

Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study

Open Access
Original Article

Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients

Open Access
Original Article

Impact of presurgical systemic therapy on perioperative outcomes of renal cell carcinoma with inferior vena cava tumor thrombus

Original Article

Neu im Fachgebiet Onkologie

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

14.03.2025
Früherkennungsuntersuchung
Nachrichten

Daten aus den Niederlanden zeigen, dass Krebsfrüherkennungsmaßnahmen für Menschen mit Störungen der Intelligenzentwicklung häufig nicht zugänglich sind. Wie kann diese Lücke geschlossen werden?

Perkutane Ablation – ungenutztes Potenzial für die Schmerztherapie?

12.03.2025
Tumorschmerz
Nachrichten

Geht es nach US-Versicherungsdaten, ist die perkutane Ablation eine vorteilhafte, aber zu selten genutzte Option in der Schmerzlinderung von Personen mit bestimmten Tumoren. Wichtige Fragen bleiben allerdings unbeantwortet.

Reduzieren Kälte und Kompression die CIPN-Gefahr in den Händen?

12.03.2025
Nebenwirkungen der Krebstherapie
Nachrichten

Ergebnisse der deutschen POLAR-Studie sprechen dafür, dass kühlende oder komprimierende Handschuhe das Risiko für eine Taxan-induzierte periphere Neuropathie senken können. Ein paar Fragen bleiben aber offen.

BCG-Therapie kann die Zystektomie ersparen

11.03.2025
Harnblasenkarzinom
Nachrichten

Patienten und Patientinnen mit hoch- oder äußerst riskantem nicht muskelinvasivem Blasenkrebs können mithilfe von BCG-Instillationen die radikale Zystektomie mitunter vermeiden. Muss die Blase später doch entfernt werden, darf der rechte Zeitpunkt nicht verpasst werden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma